About: Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scholarly article by Katharina Kriegsmann et al published 29 January 2019 in Blood Cancer Journal

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в січні 2019 (uk) article scientifique publié en 2019 (fr) im Januar 2019 veröffentlichter wissenschaftlicher Artikel (de) scholarly article by Katharina Kriegsmann et al published 29 January 2019 in Blood Cancer Journal (en)
publication date	wds:Q61443000-E3650BC7-D216-4826-BA9C-9649B8623DE0
publication date	2019-01-29 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q61443000-7B19C25B-70E1-4B4C-AB23-49E366F093CA
language of work or name	English
exact match	wds:Q61443000-D1E1E93D-FF36-4443-878E-CE918BB2C11E
exact match	https://scigraph.springernature.com/pub.10.1038/s41408-019-0174-z
cites work	wds:Q61443000-0895636C-C886-4633-BCA0-700BD5829063 wds:Q61443000-2DF5486F-7FBF-4257-A061-A3AF6E90C945 wds:Q61443000-373D823A-45D8-492C-B2EC-8F503E0A6DF2 wds:Q61443000-3CE4D75A-DD94-42FC-A44F-692072AFE24A wds:Q61443000-3FF0313A-A7C1-4F15-8E95-7245924E6D03 wds:Q61443000-4A7D8FCE-BA54-4097-8C0B-BBB0BBC66228 wds:Q61443000-6DB2268D-6A51-4DED-953F-529C5DD4D547 wds:Q61443000-71A03A7F-802D-4AE2-A20C-B951D8CAAC75 wds:Q61443000-7F63FEDB-CDD6-45AB-90E5-AD7A9A57F860 wds:Q61443000-88E18FD0-9DD6-437B-8616-0C63F450058D wds:Q61443000-8F137790-361D-4B29-AE6E-A2485C46AE65 wds:Q61443000-91695B75-13EC-4B76-A31C-8927241CCAD0 wds:Q61443000-97B846DF-4BF8-4A38-BFB7-7F2EAFA93B7C wds:Q61443000-A9C534E5-200B-4242-9169-3E557911FDF1 wds:Q61443000-AB4B9643-4D92-4460-9850-20078E35389E wds:Q61443000-AB6BD4E6-4F00-45F3-BFAE-560F6572E170 wds:Q61443000-B081663A-F5ED-4472-B9EC-1F4EA8525D89 wds:Q61443000-B47A7F35-98F8-4CC4-BB87-FD00E14E527E wds:Q61443000-C4ED77B1-1D86-4FB1-9B32-680F79828FB8 wds:Q61443000-CCCB2CF3-E1C7-4BD7-A1D8-B3AF55336E2A wds:Q61443000-D726457F-DD7C-4E6B-A70E-9BE2D1BDB4B1 wds:Q61443000-D7A4CCF0-B076-415C-8AE2-119A2976E5E3 wds:Q61443000-D7A7166C-4870-4384-834D-1D4D6E4EEB8A wds:Q61443000-DA11294E-E052-473C-B39E-5041DFE3C7C0 wds:Q61443000-E258A3A7-3927-49AB-975F-66CCBC2EFE0A wds:Q61443000-E341873D-A82A-4864-A24E-B37D58082AA5 wds:Q61443000-F03D29EA-AF7E-4103-8A33-74B402F98EFD wds:Q61443000-FCFA493E-26C5-42B7-8C46-30DC8C8AB4DD
cites work	Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma IRF4 addiction in multiple myeloma The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM). CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease. Lack of CD27 in myeloma delineates different presentation and outcome BSAP (Pax5)-importin alpha 1 (Rch1) interaction identifies a nuclear localization sequence Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? Immunophenotype of normal and myelomatous plasma-cell subsets Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma Early genetic events provide the basis for a clinical classification of multiple myeloma. High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide Genomics of Multiple Myeloma. The novel mechanism of lenalidomide activity. IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma
author name string	wds:Q61443000-067FE457-39ED-4B0C-9E45-138D1F19D9BC wds:Q61443000-0B069B68-606A-44A9-82C2-47185AED604E wds:Q61443000-25C6CC94-E6DB-4CAF-A691-73FBAC354715 wds:Q61443000-2731D086-5ACC-4AB4-9436-5C4380183CA4 wds:Q61443000-30EFF533-7E28-43F0-BFC6-7BB575FD3259 wds:Q61443000-3DD483FE-966E-481E-A333-4EE7B994179D wds:Q61443000-4F214050-7D7E-4644-B00D-2A84F886D0B3 wds:Q61443000-6D6B9655-1F26-4602-8DF8-B80A142969E0 wds:Q61443000-7C6E1E15-5B0D-4982-8E7F-E27B46DB8577 wds:Q61443000-8DDA564F-5FFF-4B38-8BE7-F2A850E4D5C9 wds:Q61443000-906D0B67-900C-482C-A71B-8E098ADB91B3 wds:Q61443000-AD0E0C4E-F3B1-4BE5-AB92-7C03F21BFBFC wds:Q61443000-B610D757-D565-46CF-89DE-898F9164C18B wds:Q61443000-C3E1AC9A-7791-4E94-BD1A-FB65D81F9732 wds:Q61443000-CA4BDF0A-3295-491B-A020-1E4F365F3049 wds:Q61443000-DAB6D6E9-C51A-49E4-8FB9-F1F95EFAC639 wds:Q61443000-E8181E39-979F-4441-93EF-D83BBBDC4C83 wds:Q61443000-FA03EF2C-A608-4D51-BBC8-C30259D2FEB3
author name string	Marc S Raab Anna Jauch Axel Benner Markus Munder Carsten Müller-Tidow Mathias Hänel Natalia Becker Jens Hillengass Uta Bertsch Anja Seckinger Michael Hundemer Maximilian Merz Jan Dürig Roland Fenk

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software